COMMUNIQUÉS West-GlobeNewswire

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

02/04/2025 - 13:30

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D [...]

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

02/04/2025 - 13:30

EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter [...]

Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board

02/04/2025 - 13:30

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Grove AI , pioneer in life science automation using agentic AI, today announced the formation of its inaugural Advisory Board. Comprised of prominent leaders from [...]

Aurora Spine Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™ Sacroiliac Fusion System

02/04/2025 - 13:30

CARLSBAD, California, April 02, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve [...]

Moringa: Learn Why These Moringa Powder Supplements Are Transforming Energy, Immunity, and Overall Health

02/04/2025 - 13:13

LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) -- Moringa Oleifera, often called the “Miracle Tree,” is rapidly gaining recognition in the U.S. as a superfood for its remarkable health benefits. From boosting daily energy [...]

Cartesian Therapeutics Announces New Employment Inducement Grants

02/04/2025 - 13:05

FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, [...]

Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec

02/04/2025 - 13:00

MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis [...]

Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec

02/04/2025 - 13:00

MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien- [...]

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

02/04/2025 - 13:00

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today [...]

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

02/04/2025 - 13:00

Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease NEWTON, Mass., April 02, 2025 (GLOBE [...]

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

02/04/2025 - 13:00

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical [...]

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

02/04/2025 - 12:00

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) [...]

The Ensign Group Adds Two Operations in California

02/04/2025 - 12:00

SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

02/04/2025 - 12:00

MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- [...]

Former EPA Flint Emergency Coordinator Expands Groundbreaking Drinking Water Training Program

02/04/2025 - 12:00

Applying Lessons Learned from the Flint Water Crisis to Strengthen Safe Drinking Water Efforts Nationwide CHICAGO, April 02, 2025 (GLOBE NEWSWIRE) -- Environmental & Public Health International (EPHI), an emerging [...]

The Ensign Group Purchases Two Facilities in Washington

02/04/2025 - 12:00

SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

02/04/2025 - 12:00

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]

The Ensign Group Expands in California

02/04/2025 - 12:00

SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)

02/04/2025 - 11:00

Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and [...]